Compare Cassava Sciences Inc (FLNA) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs LTC Properties Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while LTC Properties Inc trades at $41.01 (market cap $2.05B). The key difference: LTC Properties Inc is far larger — about 38.6× Cassava Sciences Inc's market cap, and LTC Properties Inc pays a 5.69% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LTC | |
|---|---|---|
Market Cap | $53.14M | $2.05B |
Sector | Health | Real Estate |
52-Week High | $4.64 | $40.36 |
52-Week Low | $1.09 | $33.98 |
Enterprise Value | -$33.43M | $2.90B |
Dividend Yield | — | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
LTC Properties (NYSE: LTC) trades at $40.54, up 1.27% on the day, with a bullish technical signal from moving averages. The healthcare REIT shows strong profitability with a 39.09% net income margin and consistent monthly dividends of $0.19 per share. Recent strategic moves include expanding its SHOP portfolio with $73M and $54M acquisitions in 2026 and enhancing its credit facility to $1.1B, signaling aggressive growth in senior housing.
The outlook is cautiously optimistic. The shift toward SHOP properties aims to materially change the growth profile by year-end 2026, supported by aging demographics. Key risks include recent earnings misses, rising debt levels, and execution of the portfolio transition. Analyst consensus leans Hold (59%), with mixed sentiment between strong fundamentals and near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
